• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RadNet Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    6/12/25 4:20:27 PM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email
    RadNet, Inc. 8-K
    false 0000790526 0000790526 2025-06-10 2025-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) June 10, 2025

     

    RadNet, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33307   13-3326724
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer Identification No.)

     

    1510 Cotner Avenue    
    Los Angeles, California   90025
    (Address of Principal Executive Offices)   (Zip Code)

      

    Registrant’s Telephone Number, Including Area Code: (310) 445-2800

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.0001 par value RDNT NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On June 11, 2025, RadNet, Inc. (the “Company”) and the Company’s wholly-owned subsidiary, Radnet Management, Inc. (the “Borrower”), entered into Incremental Amendment No. 2 to Credit and Guaranty Agreement (the “Second Amendment”) with the lenders and financial institutions named therein, Barclays Bank PLC, as administrative agent and collateral agent on behalf of the lenders, and substantially all of the Company’s wholly-owned domestic subsidiaries and certain of its affiliates as guarantors. The Second Amendment amends the Third Amended and Restated First Lien Credit and Guaranty Agreement dated as of April 18, 2024, as amended on November 26, 2024 (the “Existing Credit Agreement” and, as amended by the Second Amendment, the “Credit Agreement”) and contains the following material terms:

     

    Borrowing. Pursuant to the Second Amendment, Barclays Bank PLC, as lender, agreed to provide the Borrower an Incremental Term Commitment (as defined by the Existing Credit Agreement) in an aggregate principal amount of $100.0 million (the “2025 Incremental Term Loan”), which will be added to and form a part of the existing term loan under the Existing Credit Agreement (the “Existing Term Loan,” together with the 2025 Incremental Term Loan, the “Term Loan”).

     

    Use of Proceeds. Borrower plans to use the proceeds from the 2025 Incremental Term Loan for future acquisitions and general corporate purposes.

     

    Payments. Pursuant to the Second Amendment, the Borrower will be required to make quarterly payments of principal on the Term Loan in the amount of approximately $2.4 million compared to approximately $2.2 million prior to the entry of the Second Amendment.

     

    Maturity. The maturity date for the 2025 Incremental Term Loan is April 18, 2031, coincident with the maturity date of the $868.4 million balance of the Existing Term Loan under the Existing Credit Agreement.

     

    All other terms of the Credit Agreement (as amended by the Second Amendment), including the maturity of the Term Loan and revolving credit facility, use of proceeds, payment terms, covenants, events of default and security remain unchanged.

     

    A copy of the Second Amendment is included as Exhibit 10.1 to this report and is incorporated herein by this reference. The foregoing summary description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to Exhibit 10.1.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 of this report is incorporated herein by reference.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company, held on June 10, 2025, the stockholders considered and approved three proposals, each of which is described in more detail in the Company’s 2025 definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2025.

     

    At the Annual Meeting, a total of 68,229,203 shares of the Company’s common stock, representing approximately 90.95% of the 75,012,892 shares outstanding and eligible to vote as of the April 16, 2025 record date, were represented in person or by proxy, constituting a quorum. The results detailed below represent the final voting results as certified by the Inspector of Elections:

     

     

     

     2 

     

     

    Proposal 1

     

    The stockholders elected the following seven directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified based on the following votes:

     

    Director   For   Withheld   Broker Non-Votes
    Howard G. Berger, M.D.   59,789,729   1,530,420   6,909,054
    A. Gregory Sorensen, M.D.   58,460,227   2,859,922   6,909,054
    Laura P. Jacobs   51,920,870   9,399,279   6,909,054
    Lawrence L. Levitt   54,621,454   6,698,695   6,909,054
    Gregory E. Spurlock   56,689,679   4,630,470   6,909,054
    David L. Swartz   55,012,427   6,307,722   6,909,054

     

    Proposal 2

     

    The proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025 was approved based on the following votes:

     

    For   Against   Abstentions
    67,788,289   422,697   18,217

     

    Proposal 3

     

    The non-binding advisory vote to approve the compensation of the Company’s Named Executive Officers disclosed in the Company’s 2025 definitive proxy statement was approved based on the following votes:

     

    For   Against   Abstentions   Broker Non-Votes
    50,822,611   10,417,523   80,015   6,909,054

     

    Item 7.01. Regulation FD.

     

    The Company issued a press release related to the 2025 Incremental Term Loan. The information contained in this Item 7.01 and in Exhibit 99.1 attached to this Report is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section. Furthermore, such information shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
         
    10.1   Amendment No. 2 to Credit and Guaranty Agreement, dated as of June 11, 2025, by and among Radnet Management, Inc., a California corporation, RadNet, Inc., a Delaware corporation, certain subsidiaries and affiliates of Radnet Management, Inc., as Guarantors, the Lenders and other financial institutions from time to time party thereto, and Barclays Bank PLC, as Administrative Agent and Collateral Agent.
    99.1   Press Release dated June 11, 2025.
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

     

     

     3 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 12, 2025 RADNET, INC.  
         
           
      By: /s/ Mark Stolper  
      Mark Stolper  
      Chief Financial Officer  

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     4 

    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    SEC Filings

    View All

    SEC Form 10-K filed by RadNet Inc.

    10-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 5:17:51 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 7:01:44 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 7:00:48 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP of Fin Planning, CAO Patel Mital was granted 20,667 shares, increasing direct ownership by 12% to 200,175 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:14 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Pres & CEO, Digital Health Wesdorp Cornelis was granted 20,330 shares, increasing direct ownership by 38% to 73,825 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:10 PM ET
    $RDNT
    Medical Specialities
    Health Care

    EVP and Chief Legal Officer Katz David Jeffrey was granted 19,289 shares, increasing direct ownership by 27% to 90,866 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:12 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DeepHealth Unveils Industry's Most Comprehensive Portfolio of Native Clinical AI Solutions at ECR 2026

    VIENNA, March 04, 2026 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities — MR, CT, X-ray, Mammography and Ultrasound — and spanning detection, assessment and monitoring, all available on one platform. With this week's acquisition of Gleamer, DeepHealth further expands its leadership in advancing screening tools into routine imaging and acute diagnostic care, uniquely positioned to deliver the next era of AI-powered health informatics.  "As European na

    3/4/26 7:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Butterfly Network (NYSE:BFLY), Tempus AI (NASDAQ:TEM), RadNet (NASDAQ:RDNT), and GE HealthCare (NASDAQ:GEHC) are conv

    3/3/26 12:19:00 PM ET
    $BFLY
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Computer Software: Programming Data Processing

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

    Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of

    3/2/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Acquires Gleamer, Making RadNet's DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide

    Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications.Gleamer's leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer's solutions will provide the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities. Gleamer achieved an Annual Recurring Revenue ("ARR") i compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 millio

    3/2/26 5:45:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care